, subtype Meningothelial: 23.7% (33/139) Fibrous or fibroblastic: 7.2% (10/139) Transitional or mixed: 15.1% (21/139) Psammomatous: 5.1% (7/139

, Mitosis (/1.6 mm²) (mean ± SEM, range)

. Ki-67,

, CD34 MVD (mean ± SD ; range) 246 ± 103, vol.962, pp.76-1038

, CD105 MVD (mean ± SD ; range) 49 ± 37, vol.379, pp.0-379

, MVP: microvascular proliferation; MVD: microvessel density; NA: not available; SEM: standard error of mean; SD: standard deviation; WHO: World Health Organization

A. Moradi, V. Semnani, and H. Djam, Pathodiagnostic parameters for meningioma grading, J Clin Neurosci, vol.15, pp.1370-1375, 2008.

A. Vranic, M. Popovic, and A. Cor, Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients, Neurosurgery, vol.67, pp.1124-1156, 2010.

J. Jaaskelainen, Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis, Surg Neurol, vol.26, pp.461-470, 1986.

C. Daumas-duport, M. L. Tucker, and H. Kolles, Part II: A new grading system based on morphological and imaging criteria, J Neurooncol, vol.34, pp.61-78, 1997.

V. Barresi, S. Cerasoli, and E. Vitarelli, Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas, Acta Neuropathol, vol.114, pp.147-56, 2007.

M. Shibuya, Pathology and molecular genetics of meningioma: recent advances, Neurol Med Chir (Tokyo), vol.55, pp.14-27, 2015.

T. A. Dolecek, J. M. Propp, and N. E. Stroup, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in, Review) Neuro Oncol, vol.14, issue.5, pp.1-49, 2005.

D. N. Louis, A. Perry, and G. Reifenberger, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Review) Acta Neuropathol, vol.131, pp.803-823, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

M. J. Riemenschneider, A. Perry, and G. Reifenberger, Histological classification and molecular genetics of meningiomas, Review) Lancet Neurol, vol.5, pp.1045-54, 2006.

F. Sahm, D. Schrimpf, and A. Olar, TERT Promoter Mutations and Risk of Recurrence in

, Gov't) J Natl Cancer Inst, vol.108, 2016.

V. E. Clark, E. Z. Erson-omay, and A. Serin, Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, Gov't) Science, vol.339, pp.1077-80, 2013.

A. Perry, B. W. Scheithauer, and S. L. Stafford, Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications, Cancer, vol.85, pp.2046-56, 1999.

A. Rausing, W. Ybo, and J. Stenflo, Intracranial meningioma-a population study of ten years, Acta Neurol Scand, vol.46, pp.102-112, 1970.

D. Simpson, The recurrence of intracranial meningiomas after surgical treatment, J Neurol Neurosurg Psychiatry, vol.20, pp.22-39, 1957.

C. Boskos, L. Feuvret, and G. Noel, Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. (Evaluation Studies), Int J Radiat Oncol Biol Phys, vol.75, pp.399-406, 2009.

C. Haie-meder, P. Brunel, and C. Cioloca,

, Bull Cancer Radiother, vol.82, pp.35-44, 1995.

K. C. Shih, S. Chowdhary, and P. Rosenblatt, Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma, J Neurooncol, vol.18, pp.1-11, 2016.

S. Pistolesi, L. Boldrini, and S. Gisfredi, Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer, Comparative Study Research Support, vol.30, pp.1031-1035, 2003.

F. Tanaka, H. Oyanagi, and K. Takenaka, Glomeruloid microvascular proliferation is superior to intratumoral microvessel density as a prognostic marker in non-small cell lung cancer, Gov't) Cancer Res, vol.63, pp.6791-6795, 2003.

R. Peddinti, R. Zeine, and D. Luca, Prominent microvascular proliferation in clinically aggressive neuroblastoma, Gov't) Clin Cancer Res, vol.13, pp.3499-506, 2007.

D. J. Brat and E. G. Van-meir, Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. (Comment Review), Am J Pathol, vol.158, pp.789-96, 2001.

N. O. Kandemir, Z. I. Narli, and M. Kalayci, A rare pattern of angiogenesis in meningiomas: glomeruloid microvascular proliferation, Case Reports) Turk Neurosurg, vol.24, pp.765-774, 2014.

D. 'haene, N. Catteau, X. Maris, and C. , Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas, Non-U.S. Gov't) Br J Haematol, vol.140, pp.402-412, 2008.

S. Matsubara, A. Bourdeau, and K. G. Terbrugge, Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations, Non-U.S. Gov't) Stroke, vol.31, pp.2653-60, 2000.

R. S. Saad, Y. El-gohary, and E. Memari, Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. (Comparative Study), Hum Pathol, vol.36, pp.955-61, 2005.

S. Behrem, K. Zarkovic, and N. Eskinja, Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma, Croat Med J, vol.46, pp.417-439, 2005.

S. Ding, C. Li, and S. Lin, Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. (Comparative Study), Hum Pathol, vol.37, pp.861-867, 2006.

Y. Yao, T. Kubota, and H. Takeuchi, Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. (Comparative Study Research Support, Gov't) Neuropathology, vol.25, pp.201-207, 2005.

D. N. Louis, H. Ohgaki, and O. D. Wiestler, WHO Classification of Tumours of the Central Nervous System, Revised. Fourth Edition, 2016.

O. Straume and L. A. Akslen, Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. (Comparative Study Research Support, Gov't) Angiogenesis, vol.6, pp.295-301, 2003.

Q. T. Ostrom, H. Gittleman, and J. Fulop, CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States, Neuro Oncol, vol.17, pp.1-62, 2008.

F. P. Nunes, V. L. Merker, and D. Jennings, A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma, Extramural) PLoS One, vol.8, pp.281-289, 2013.

R. Jensen and J. Lee, Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia, vascularity, and proliferation, Gov't) Neurosurgery, vol.71, pp.146-56, 2012.

M. Preusser, M. Hassler, and P. Birner, Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches, Gov't) Clin Neuropathol, vol.31, pp.352-60, 2012.

Y. Sugita, Y. Takase, and D. Mori, Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival, J Neurooncol, vol.82, pp.249-56, 2007.

J. R. Landis and G. G. Koch, The measurement of observer agreement for categorical data, Biometrics, vol.33, pp.159-74, 1977.

S. W. Coons, P. C. Johnson, and B. W. Scheithauer, Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas, Cancer, vol.79, pp.1381-93, 1997.

O. Straume, P. O. Chappuis, and H. B. Salvesen, Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers, Cancer Res, vol.62, pp.6808-6819, 2002.

V. Callot, D. Galanaud, and D. Figarella-branger, Correlations between MR and endothelial hyperplasia in low-grade gliomas, Non-U.S. Gov't) J Magn Reson Imaging, vol.26, pp.52-60, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00169038

C. L. Rogers, A. Perry, and S. Pugh, Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539, Extramural) Neuro Oncol, vol.18, pp.565-74, 2016.

T. Sakurai, H. Okumura, and M. Matsumoto, Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma, Gov't) Anticancer Res, vol.34, pp.3431-3439, 2014.

Y. Miyata, Y. Sagara, and S. Watanabe, CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34, Virchows Arch, vol.463, pp.673-682, 2013.

X. Kong, Y. Wang, and S. Liu, CD105 Over-expression Is Associated with Higher WHO Grades for Gliomas, Mol Neurobiol, vol.53, pp.3503-3515, 2016.

V. Barresi, C. Alafaci, and F. Salpietro, Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density?, Oncol Rep, vol.20, pp.485-92, 2008.

M. A. Vogelbaum, L. Rogers, C. Linskey, and M. A. , Opportunities for clinical research in meningioma, J Neurooncol, vol.99, pp.417-439, 2010.

A. Borg, J. Ekanayake, and R. Mair, Preoperative particle and glue embolization of meningiomas: indications, results, and lessons learned from 117 consecutive patients, Neurosurgery, vol.73, pp.244-51, 2013.

J. Y. Chun, M. W. Mcdermott, and K. R. Lamborn, Delayed surgical resection reduces intraoperative blood loss for embolized meningiomas, Neurosurgery, vol.50, pp.1231-1236, 2002.

M. Bendszus, I. Martin-schrader, and H. P. Schlake, Embolisation of intracranial meningiomas without subsequent surgery. (Comparative Study), Neuroradiology, vol.45, pp.451-456, 2003.

B. Ragel and R. L. Jensen, New approaches for the treatment of refractory meningiomas, Case Reports) Cancer Control, vol.10, pp.148-58, 2003.

Z. S. Shi, L. Feng, and X. B. Jiang, Therapeutic embolization of meningiomas with Onyx for delayed surgical resection, Case Reports) Surgical neurology, vol.70, pp.478-81, 2008.

L. Nayak, F. M. Iwamoto, and J. D. Rudnick, Atypical and anaplastic meningiomas treated with bevacizumab, J Neurooncol, vol.109, pp.187-93, 2012.
DOI : 10.1007/s11060-012-0886-4

E. Lou, A. L. Sumrall, and S. Turner, Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series, J Neurooncol, vol.109, pp.63-70, 2012.

A. B. Apolo, F. H. Karzai, and J. B. Trepel, A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma, Clin Genitourin Cancer, 2016.

F. H. Karzai, A. B. Apolo, and L. Cao, A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. (Clinical Trial, Phase I), BJU Int, vol.116, pp.546-55, 2015.

M. S. Gordon, F. Robert, and D. Matei, An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. (Clinical Trial, Phase I Multicenter Study Research, Gov't) Clin Cancer Res, vol.20, pp.5918-5944, 2014.

C. Sundberg, J. A. Nagy, and L. F. Brown, Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery, Am J Pathol, vol.158, pp.1145-60, 2001.

T. Sakuma, T. Nakagawa, and K. Ido, Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas, Non-U.S. Gov't) J Neurooncol, vol.88, pp.143-55, 2008.